Myriad Genetics (MYGN) Expected to Announce Quarterly Earnings on Tuesday

Myriad Genetics (NASDAQ:MYGN - Get Free Report) is projected to announce its Q1 2025 earnings results after the market closes on Tuesday, May 6th. Analysts expect Myriad Genetics to post earnings of ($0.05) per share and revenue of $200.37 million for the quarter.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The firm had revenue of $210.60 million for the quarter, compared to the consensus estimate of $210.35 million. During the same period in the prior year, the business earned ($0.12) EPS. On average, analysts expect Myriad Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Myriad Genetics Stock Performance

Shares of Myriad Genetics stock traded down $0.28 during mid-day trading on Thursday, hitting $7.13. 3,944,606 shares of the stock were exchanged, compared to its average volume of 977,588. Myriad Genetics has a 12 month low of $6.94 and a 12 month high of $29.30. The company has a 50-day simple moving average of $8.97 and a 200 day simple moving average of $13.29. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The company has a market capitalization of $657.18 million, a P/E ratio of -5.48 and a beta of 1.87.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. StockNews.com raised shares of Myriad Genetics from a "hold" rating to a "buy" rating in a research report on Thursday, April 10th. Raymond James reiterated an "outperform" rating and issued a $19.00 price objective (down previously from $27.00) on shares of Myriad Genetics in a research note on Tuesday, February 25th. Piper Sandler upgraded Myriad Genetics from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $11.50 to $12.50 in a research note on Wednesday, March 12th. The Goldman Sachs Group dropped their price objective on Myriad Genetics from $18.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Finally, Stephens reiterated an "equal weight" rating and issued a $20.00 price objective on shares of Myriad Genetics in a research note on Thursday, January 16th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $20.61.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.